DUBLIN–(BUSINESS WIRE)–The “Global Peptide Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Innovative and Generic), By Route of Administration, By Synthesis Technology, By Type of Manufacturers, By Application, By Regional Outlook and Forecast, 2022-2028” report has been added to ResearchAndMarkets.com’s offering.
The Global Peptide Therapeutics Market size is expected to reach $58.4 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.
Peptide therapeutics are polypeptides or peptides (oligomers or short polymers of amino acids) that are utilized to treat disorders. Peptide treatments replicate natural peptide functions such as hormones, neurotransmitters, growth factors, ion channel ligands, and anti-infectives. Because peptides may be digested by the body, they are thought to be reasonably safe and well-tolerated.
Liraglutide, the most popular diabetic medicine on the market, contains a lipid chain that increases plasma circulation and provides long-term absorption. Liraglutide is a GLP-1 agonist that self-assembles itself into an alpha-helical structure and only needs to be consumed once a day. Liraglutide’s half-life in the blood is lengthened by approximately 13-14 hours due to lipid conjugation of a palmitoyl chain to a lysine residue at position 26.
This is attributed to the palmitoyl chain’s ability to bind albumin non-covalently, delaying DPP IV’s proteolytic action and enabling fast renal clearance. The inclusion of the lipid chain could further extend the half-life by preventing the DPP IV enzyme from degrading sterically.
Lanreotide, an octapeptide, is another peptide that may self-assemble. This medication is a synthetic counterpart of the peptide hormone somatostatin, which is used to alleviate acromegaly (a malfunction where the body produced excessive amounts of growth hormone).
Lanreotide assembles itself into monodisperse liquid crystalline nanotubes when exposed to water. The nanotubes are composed of dimers that self-assemble into a 2D lattice that is kept together by antiparallel ?-sheets and lateral chain connections. Studies on self-assembling amyloid aggregates created by peptide hormones and neuropeptides have provided more insight into how self-assembly, as well as peptide hormones, are connected.
Market Growth Factors
Rising number of applications
Cardiovascular disease (CVD) is still the major cause of death and morbidity around the world. Many interventions are being tested to ameliorate pathological cardiovascular problems, however, there have been few new drugs licensed for intervention or treatment. As a result, novel techniques for treating CVD are urgently needed.
The treatment of contributory risk factors and underlying mechanisms, such as inflammation, obesity, hyperglycemia, and hypercholesterolemia is frequently used to prevent vascular problems. The pharmaceutical industry has traditionally resisted using peptides as therapeutic agents due to their limited stability, size, rate of breakdown, and poor distribution. However, there has been a renaissance in the development of peptides and their synthetic derivatives for therapeutic intervention in recent years.
Increasing cases of cancer all over the world
Cancer is the second leading cause of death, accounting for a considerable number of deaths all over the world in 2013. The rate of cancer in developed countries is significantly higher than in developing countries. The prevalence of known risk factors is predicted to rise in these under-developed nations due to population growth and aging, as well as an increased prevalence of known risk factors.
Lung cancer is the largest cause of death from cancer in men around the world, but only in industrialized countries, while breast cancer is the leading reason of cancer death in developing countries. Somatic gene mutations that change the function of the proteins they encode have been linked to cancer. Most solid tumors, like those of the brain, colon, breast, and pancreas, exhibit somatic changes.
Market Restraining Factors
Side effects and risks related to peptide therapy
Natural polypeptides like hormones, growth factors, and neurotransmitters, unlike synthesized peptide medications, are considered to play an important function in normal physiology. Membrane impermeability and in vivo instability are two key disadvantages of peptide medicines.
Proteolytic degradation of peptide medicines in serum diminishes the bioavailable concentration and reduces the drug’s half-life. To keep the medicine at a clinically effective concentration, routine dosing may be required. To avoid proteolytic degradation and enhance the in vivo half-life of peptide medicines, a variety of chemical modification approaches have been used.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Innovative
- Generic
By Route of Administration
- Parenteral Route
- Pulmonary
- Mucosal
- Oral Route
- Others
By Synthesis Technology
- Liquid Phase Peptide Synthesis (LPPS)
- Solid Phase Peptide Synthesis (SPPS)
- Hybrid Technology
By Type of Manufacturers
- In-house
- Outsourced
By Application
- Metabolic
- Cardiovascular Disorder
- GIT & Renal
- Antiinfection & Dermatology
- Respiratory
- Central Nervous System
- Cancer
- Pain
- Others
By Geography
- North America
- Europe
- Asia Pacific
- LAMEA
Key Market Players
- Eli Lilly And Company
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
- GlaxoSmithKline PLC
- Takeda Pharmaceutical Company Limited
- Lonza Group AG
- Amgen, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/ljnfrw
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900